Roswin Side Effects

The adverse events seen with rosuvastatin are generally mild and transient.
Nervous system disorders: Common: headache, dizziness.
Very rare: polyneuropathy, memory loss.
Gastrointestinal disorders: Common: constipation, nausea, abdominal pain.
Rare: pancreatitis.
Musculoskeletal, connective tissue and bone disorders: Common: myalgia.
Rare: myopathy, including myositis and rhabdomyolysis.
As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis in post-marketing use is higher at the highest marketed dose.
Very rare: arthralgia.
General disorders: Common: asthenia.
Immune system disorders: Rare: hypersensitivity reactions including angioedema.
Skin disorders: Uncommon: pruritus, rash, urticaria.
As with other HMG-CoA reductase inhibitor, the incidence of adverse drug reactions tends to increase with increasing dose.
Skeletal Muscle Effects: Rare cases of rhabdomyolysis which were occasionally associated with impairment of renal function.
Laboratory Effects: As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases and CK have been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (>5x ULN), treatment should be discontinued. Increases in HbA1c have also been observed in patients treated with rosuvastatin.
Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40 mg. This is usually transients or intermittent, and not predictive of acute progressive renal disease. An assessment of renal function should be considered during routine follow up of patients treated with a dose of 40 mg.
Hepatobiliary disorders: Very rare: Jaundice, hepatitis.
Rare: increased hepatic transaminase.
Psychiatric disorders: Unknown: depression, sleep disorder (including insomnia and nightmares).